So if you — again, the colors are tricky. But if you look at the colors here, given more of our recent efforts into biopharma, you’ll see that a lot, just under half of our newer programs that are early in development are in biopharma. So again, I’m happy to see that. All right. After those programs hit 100%, if they do, and some fail before they do, but if they hit 100%, then the customer — and the customer chooses to move forward with them, they enter commercialization. And so you can see we have on the bottom 15 programs that are being actively commercialized now, meaning the customer is moving forward with taking them through regulatory like Synlogic in Phase II trials or they’re going into scale up, like Centrient. Many customers don’t announce this.
Again, this is like product development. So it can be held close to the vest, but we’ve shared a couple where they have. And eventually, that commercialization process finishes. And we have 6 programs that are kind of fully commercial. In other words, they’re giving us royalties, or it’s equity on a program that the customer has put into the market. So we’re very excited to see the pipeline you saw on the last couple of slides, hopefully move into these buckets as the programs get to 100% complete, and we’re extra excited to add many more programs to the pipeline in the coming quarters. So we need many more slides. And the scale of all this is what makes Ginkgo special as a platform rather than a product company in biotech. I’m really, really proud of this scale.
It’s pretty awesome to see it all in one place. Okay. I’d like to cover our last strategic topic for the day, which is about the national security priority that’s emerging around biosecurity and Ginkgo’s position in this emerging space. So just the past few weeks, have seen a ton of discussion around the convergence of AI and biology. I’ve linked a bunch here, articles here, which are good reading for those interested in the space. Last week, Anna Marie, our new Head of AI, which is why you got to see Megan at the start of this presentation instead of Anna Marie, and Matt McKnight, the General Manager of our biosecurity business, were in London during the AI Safety Summit to discuss this. And we’ve been spending quite a bit of time down in Capitol Hill discussing both how to accelerate U.S. leadership in AI in biotech, but also how to advance these technologies responsibly.
So while biosecurity needs to exist, irrespective of its potential for misuse by humans. And the reason for this is, whether we do it or not, Mother Nature is throwing off epidemics and pandemics on our own. And so we do need biosecurity regardless for public health. We’re seeing that biology is becoming a more clear national security priority with the advancement of AI tools, which is driving more global government focus on what needs to be done to ensure the technology is deployed responsibly. We’ve seen real momentum in defense technologies recently, I’d say, as a category. And with particular leadership from our Board Chair, Shyam Sankar at Palantir, you can read a really nice blog post of Shyam’s link there. There is not yet a defense tech business for biology, but it is increasingly clear that the defense community believes we have a critical gap when it comes to biology.
Ginkgo has been building biodefense tools for years now to protect our platform, to respond to COVID in a big way and, more recently, mapping out what a more scalable biodefense ecosystem might look like, which I’ll talk about here. Okay. So Ginkgo plays across the tech stack for biodefense, but we see a significant investment and product gap in the area of monitoring and analytics as most of the investment to date has been on this third box at the bottom, response, so things like vaccines and therapeutics. And that’s in part because kind of our approach to infectious disease has been, “Wait until it gets out of control and then do something about it.” And with — work hard if we can to put a damper on it, but hey, things are going to happen, and we got to be able to respond after the fact.
That’s been the overwhelming investment as opposed to prevention and early detection. I think the impact of COVID has changed that calculus. You have countries looking and saying, hey, the national security effects of this mean we can’t just let it happen and clean it up afterwards. We need to be able to detect and respond. And you can think about this a bit like cybersecurity, right? Your computer is constantly monitoring for something dangerous, characterizing it, addressing the threat right as it comes about. In biosecurity, we want to do the exact same thing. We want to build that infrastructure to be constantly monitoring leverage AI to reduce the time to threat detection and then mitigation. And it could be even a different kind of mitigation than vaccines.
